SPOTLIGHT: Analyst: AZ "worst performer" in pharma

So, Dresdner Kleinwort, tell us how you really feel about AstraZeneca. The investment bank, which just started covering AstraZeneca's stock, minced no words in its first report. The company's in "serious trouble," the analysts said, and quite possibly will be the worst performer in Big Pharma for the next eight years. Report